NovaSight

NovaSight is a pioneering startup that aims to revolutionize pediatric vision care through cutting-edge technologies. Established in 2016 and headquartered in Israel, NovaSight is committed to preventing pediatric vision loss by integrating eye-tracking and AI technologies. The company's flagship product, CureSight™, utilizes sophisticated real-time 3D image processing algorithms to treat amblyopia (lazy-eye) while children enjoy their favorite movies or TV shows at home. Moreover, the system provides real-time treatment monitoring, tele-medicine features, and AI-driven protocol adjustments. In addition to treatment, NovaSight addresses the limitations of traditional vision assessment methods with EyeSwiftPRO®, an automated, portable eye-tracking system designed to provide accurate and objective assessments of various vision impairments within seconds. This innovation significantly enhances the efficiency and accuracy of vision assessments for children, particularly toddlers. The last significant development for NovaSight occurred on 13 July 2020 with a substantial $8.00M Series A investment from Rimonci Capital. This infusion of capital testifies to the investor confidence in NovaSight's vision and technological solutions. By leveraging the latest advancements in eye-tracking and AI, NovaSight is poised to disrupt the pediatric vision care industry and make a meaningful impact in preventing vision loss among children worldwide.